Table 1 Baseline and follow up demographic and clinical characteristics of HIV-associated TB patients and comparison of mortality, Serowe/Palapye district Botswana 2013
Variables | Total N = 300 N (%) | Died Total:45 N (%) | Survivors Total:255 N (%) | P |
|---|---|---|---|---|
Age group, year | ||||
< 35 | 104 (35) | 15 (33) | 89 (35) | – |
35–59 | 179 (60) | 23 (51) | 156 (61) | – |
≥ 60 | 17 (6) | 7 (16) | 10 (4) | 0.007 |
Male sex | 170 (57) | 28 (62) | 142 (56) | 0.514 |
Unemployeda | 207 (69) | 34 (76) | 173 (68) | 0.323 |
Smokerb | 6 (2) | 3 (7) | 3 (1) | 0.008 |
Body weightc < 50 kg | 102 (34) | 17 (38) | 85 (33) | 0.023 |
Smear positive PTB | 147 (49) | 15 (33) | 132 (52) | 0.068 |
Extrapulmonary | 80 (27) | 13 (29) | 67 (26) | 0.861 |
Previous TB | 34 (11) | 4 (9) | 30 (12) | 0.799 |
Feverd | 127 (42) | 23 (51) | 104 (41) | 0.323 |
Productive coughd | 212 (71) | 31 (69) | 181 (71) | 0.863 |
Night sweatsd | 92 (30.7) | 9 (20) | 83 (33) | 0.238 |
Loss of weightd | 180 (60) | 33 (73) | 147 (58) | 0.069 |
Duration of symptoms > 3 monthsd | 44 (15) | 7 (16) | 37 (15) | 0.509 |
No ART use during TB treatment | 43 (14) | 15 (33) | 28 (11) | < 0.001 |
ART naïve | 83 (28) | 18 (40) | 65 (26) | 0.045 |
OI other than TB | 19 (6) | 12 (27) | 7 (3) | < 0.001 |
CD4 counts cells/μl at TBe < 200 | 111 (37) | 21 (47) | 90 (35) | 0.086 |
Hemoglobinf < 10 g/dl | 85 (28) | 22 (49) | 63 (25) | 0.004 |
Major Side effect | 9 (3) | 5 (11) | 4 (2) | 0.003 |
Diabetes mellitus | 5 (2) | 0 | 5 (2) | 1 |
Cotrimoxazole prophylaxis | 300 (100) | 45 (100) | 255 (100) | 1 |